The future of biomedical innovation depends in part on a new trend for all players in biomedical innovation to work together for the common goal, say 2 MIT researchers
It’s a long, expensive, risky road to turn a scientific breakthrough into a treatment that can help patients. Fewer organizations are trying to tackle the challenges alone, says a new paper from MIT researchers published August 28 in the journal Science Translational Medicine.
An essential new way to move discoveries forward has emerged in the form of multi-stakeholder collaborations involving three or more different types of organizations, such as drug companies, government regulators and patient groups, write Magdalini Papadaki, a research associate, and Gigi Hirsch, a physician-entrepreneur and executive director of the MIT Center for Biomedical Innovation.
The authors are calling for a new “science of collaboration” to learn what works and doesn’t work; to improve how leaders can design, manage and evaluate collaborations; and to help educate and train future leaders with the necessary organizational and managerial skills.
“Getting new, better, affordable drugs to the right patients faster involves a series of historically independent decisions made by different players or stakeholders,” says Hirsch. The system is uncoordinated, takes too long, and costs too much. In some cases, the drug—such as new antibiotics for life-threatening resistant infections—may never become available.
“One of the interesting paradoxes of biomedical innovation is increasingly going to be that even though we have the scientific knowledge required to provide potentially better treatments for patients—or even to prevent disease in those who are at high risk—we may be unable to help patients benefit from them anytime soon,” she says.
To help change this scenario, in the last decade, thousands of researchers, pharmaceutical and biotechnology companies, government regulators, payers, clinicians and patients have come together in more than 100 multi-stakeholder collaborations to solve some specific shared problem standing in the way of finding a cure or a better diagnostic approach.
“Multi-stakeholder collaborations provide the opportunity to create an environment that allows for new kinds of interactions among the players,” Hirsch says. The largest multi-stakeholder effort, the European Union’s Innovative Medicines Initiative (IMI) began in 2008 and has established more than 40 consortia with financial and in-kind investments totaling €2 billion. Some projects focus on specific health issues, such as Alzheimer’s disease, chronic pain, diabetes and obesity. Others tackle bigger issues, such as drug and vaccine safety and the use of stem cells for drug discovery. The success has led to a proposal to extend the effort for 10 years and €3.5 billion. Last year, the U.S. President’s Council of Advisors on Science and Technology (PCAST) recommended the U.S. form something similar.
“The prevalence of multi-stakeholder initiatives reflects a continued optimism about the value of this collaboration approach for addressing biomedical innovation bottlenecks,” the authors write in the paper. “Although the need for collaboration is no longer in question, it is worth noting the importance of this development. A willingness to share proprietary data among industry competitors represents a dramatic shift in the culture of the historically highly competitive pharmaceutical industry.”
The article reviews the history of collaborations beginning with HIV/AIDS. By the early 2000s, multi-stakeholder collaborations proliferated to address the need for important tools, such as biomarkers, that require preclinical data sharing. Since then, they have reached to encompass later stages in product development, including manufacturing, reimbursement and post-market monitoring.
Some people involved in multi-stakeholder consortia are concerned about redundancy, inefficiency and lack of productivity of some collaborative efforts, all contributing to a sense of “consortium fatigue,” the researchers write.
In a newer trend, funders and participants are seeking a smaller number of strategically coordinated initiatives that will reliably address critical gaps, Hirsch and Papadaki write. They cite the example of TransCelerate BioPharma, a group of 10 major pharmaceutical companies that came together to share and direct resources toward selected priorities in order to improve the efficiency of drug development, such as clinical trial site qualification standards.
The authors propose a rigorous evidence-based approach (the science of collaboration) to figure out what works and doesn’t work in collaborations. They recommend early steps in this new field and structuring the research to help learn from the past but also to evolve effectively as new innovation challenges emerge.
The Latest Bing News on:
Science of collaboration
- ‘Another layer of protection’ Buncombe County Schools launch test-to-stay programon January 26, 2022 at 3:00 pm
Buncombe County Schools is working to keep kids in class even if they’ve been exposed to COVID-19. The school system is launching a test-to-stay program this week in partnership with the ABC Science ...
- Breakthrough measurements of vibrating atoms in nanostructures ushers in new class of technologyon January 26, 2022 at 12:15 pm
Vanderbilt researchers Sokrates Pantelides and Joshua Caldwell are part of an international collaboration that has demonstrated a new way to manipulate and measure subtle atomic vibrations in ...
- Twelve Rutgers Professors Named Fellows of the American Association for the Advancement of Scienceon January 26, 2022 at 11:31 am
Rutgers faculty elected to the newest class of fellows for the American Association for the Advancement of Science (AAAS) are engaging in research to tackle some of the greatest mysteries of human ...
- Domino Data Lab Unleashes Model Velocity for Data Science Teams with Domino 5.0on January 26, 2022 at 11:09 am
Domino Data Lab, provider of an Enterprise MLOps platform, is releasing Domino 5.0 with new capabilities that unleash model velocity, a metric of how fast data science teams build and update models.
- Scientists observe slow photoelectron spectrum of sulfuric acid in high resolutionon January 26, 2022 at 8:21 am
As a key precursor in the formation of new particles, sulfuric acid (H2SO4) plays an important role in the formation of aerosols and clouds in the atmosphere. Gas-phase sulfuric acid molecules can ...
- What’s needed next in aging biology and biotech? New report captures insights from global, cross-sector leaderson January 26, 2022 at 7:10 am
The American Federation for Aging Research (AFAR) has released findings from a series of cross-sector think tanks hosted in 2021 to discuss the what’s needed next to strengthen the field of aging ...
- Clarivate Launches New Global Research Report on Managing Academic Publication Credit in a Collaborative Worldon January 26, 2022 at 3:26 am
Clarivate Plc (NYSE:CLVT), a global leader in providing trusted information and insights to accelerate the pace of innovation, today released a new report from the company's Institute for Scientific ...
- MBL’s Zoe Cardon is elected fellow of the American Association for the Advancement of Scienceon January 25, 2022 at 9:02 pm
Her work is interdisciplinary and collaborative; she is currently lead principal investigator ... she has brought new insights to our thinking about ecosystems science.” Among the other 2021 AAAS ...
- Final design of Advanced Manufacturing Collaborative at USC Aiken expected this yearon January 25, 2022 at 11:30 am
Final design of the Advanced Manufacturing Collaborative should be finished by late spring, cracking open the door to actual construction on the USC Aiken campus, the manager of the Savannah ...
- Unbend the spirit of scienceon January 25, 2022 at 7:26 am
New research reveals racial profiling among scientists of Chinese descent and the consequences for the US scientific community ...
The Latest Google Headlines on:
Science of collaboration
The Latest Bing News on:
- Paper Spotlight: The Local Health Effects of Biomedical Researchon January 25, 2022 at 11:02 am
NIH, the single largest funder of biomedical research in the United States, has a budget of over $40 billion in 2021, far larger than any other federal research funder. The core purpose of this ...
- Biomedical Titanium Alloys Market | Data 2022-2029 | Major Key Players Analysis, Key Trends | Dynamics with Size and Share Overviewon January 25, 2022 at 1:16 am
A recent research report on “Biomedical Titanium Alloys Market” is a thorough assessment of the state of competition in ...
- Edinburgh top for innovation but digital connectivity lags - Knight Frank reporton January 24, 2022 at 8:55 pm
Despite its top billing for, Edinburgh ranked just tenth for its digital and physical connectivity - a measure that takes into consideration fibre availability, capacit ...
- Scientist Wins Prestigious Bowes Biomedical Investigator Award for Finding ‘Anti-CRISPRs’on January 24, 2022 at 12:13 pm
Denomy, PhD, has been selected as the 2022 William K. Bowes Jr. Biomedical Investigator for his groundbreaking discovery of a secret weapon deployed by viruses in their ancient battle against bacteria ...
- Webinars outline new Cambridge Biomedical Cluster Map and Reporton January 24, 2022 at 2:39 am
The most comprehensive map of the Cambridge Biomedical Cluster ever produced has its soft launch tomorrow (Tuesday), Wednesday and Thursday with webinars masterminded by the brains behind the ...
- Photonics innovation takes centre stage in San Franciscoon January 20, 2022 at 3:23 am
Photonics West will once again bring delegates to the Moscone Center in San Francisco for its unique combination of scientific conferences, industry symposia and world-class technical exhibitions ...
- Dr. Jessica Sparks receives new position as the Associate Dean of Undergraduate Education, Technology, and Innovation.on January 19, 2022 at 4:00 pm
Dr. Jessica Sparks talks about the details of her new position in the CEC as the Associate Dean of Undergraduate Education, Technology, and Innovation.
- Japan at a Crossroads: Reconciling Drug Price Reform and Innovationon January 18, 2022 at 4:00 pm
Given the slow pace of biomedical discoveries in Japan and a concomitant shrinking of Japan’s market pos ...
- "FIRST OF ITS KIND" BSI INNOVATION LAB OPENS IN SINGAPOREon January 17, 2022 at 11:41 pm
A brand-new innovation lab will give organizations around the world the chance to harness the knowledge and expertise of BSI, the business improvement and standards company, to create innovative new ...
- Indian American Biomedical Engineer Tejal Desai Named Dean of Brown University School of Engineeringon January 14, 2022 at 1:00 pm
Tejal Desai, an Indian American biomedical engineer, has been appointed the next dean of Brown University’s School of Engineering, according to a Brown University media release.